Authors
Brian V Lananna, Celia A McKee, Melvin W King, Jorge L Del-Aguila, Julie M Dimitry, Fabiana HG Farias, Collin J Nadarajah, David D Xiong, Chun Guo, Alexander J Cammack, Jack A Elias, Jinsong Zhang, Carlos Cruchaga, Erik S Musiek
Publication date
2020/12/16
Journal
Science translational medicine
Volume
12
Issue
574
Pages
eaax3519
Publisher
American Association for the Advancement of Science
Description
Regulation of glial activation and neuroinflammation are critical factors in the pathogenesis of Alzheimer’s disease (AD). YKL-40, a primarily astrocytic protein encoded by the gene Chi3l1, is a widely studied cerebrospinal fluid biomarker that increases with aging and early in AD. However, the function of Chi3l1/YKL-40 in AD is unknown. In a cohort of patients with AD, we observed that a variant in the human CHI3L1 gene, which results in decreased CSF YKL-40 expression, was associated with slower AD progression. At baseline, Chi3l1 deletion in mice had no effect on astrocyte activation while modestly promoting microglial activation. In a mouse APP/PS1 model of AD, Chi3l1 deletion decreased amyloid plaque burden and increased periplaque expression of the microglial lysosomal marker CD68, suggesting that Chi3l1 may suppress glial phagocytic activation and promote amyloid accumulation. Accordingly …
Total citations
202120222023202416324523